ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2026
Validation and cutpoints of the treatment-induced neuropathy assessment scale (TNAS) in Chinese cancer patients: a prospective cohort study.
Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTreatment-induced peripheral neuropathy (TIPN) significantly impairs patients' quality of life, compromises the treatment process, and adversely affects prognosis. The aim of this study was to evaluate the psychometric properties of the Treatment-induced Neuropathy Assessment Scale (TNAS) and establish cutpoints in Chinese patients with cancer.
methodsIn a prospective cohort of 254 colorectal cancer patients receiving oxaliplatin, the TNAS was assessed for reliability and validity. Using patient-reported walking impairment and CTCAE grades as anchors, optimal cutpoints (CPs) for the numbness, sensory subscale, and interference subscale were derived. Group-Based Trajectory Modeling (GBTM) was subsequently used to examine the clinical utility of the cutpoints.
resultsThe TNAS showed internal consistency (α = 0.92) and repeatability (ICC = 0.85) in Chinese patients. The scale significantly discriminated between patients with and without CTCAE-defined events (1.87 ± 1.60 vs. 1.15 ± 1.72, effect size = 0.44; P < 0.001). Mild, moderate, and severe numbness strata were defined as < 3, 3-6, and ≥ 7 using the walking anchor, and as < 2, 2-4, and ≥ 5 using the CTCAE anchor. For the sensory subscale, the corresponding CPs were < 2.50, 2.50-5.49, and ≥ 5.50 per the walking anchor, versus < 0.83, 0.83-2.32, and ≥ 2.33 per the CTCAE anchor. For the interference subscale, stratification CPs were < 2.00, 2.00-4.66, and ≥ 4.67 based on the walking anchor, and < 1.67, 1.67-3.99, and ≥ 4.00 based on the CTCAE anchor. These subgroups displayed distinct longitudinal trajectories across the chemotherapy course.
conclusionThe Chinese version of the TNAS is a valid and sensitive tool for TIPN assessment. Its established cutpoints provide a quantitative basis for defining responders in clinical trials and triggering early toxicity management.
Indexed as
Identifiers
42493739What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.